MapLight Therapeutics Inc. shares jumped as much as 23% after the biotechnology firm raised $258.9 million in an initial ...
Sergey Brin’s name doesn’t appear in MapLight Therapeutics’ filings to go public, but the Google co-founder’s philanthropic ...
MapLight has become the second Massachusetts-linked biotech to go public this year. The company sold 14.75 million shares at ...
The government shutdown has left the SEC quiet, but a Peninsula biotech managed to go public anyway, lighting a path to Wall ...
MapLight Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today announced the ...
MapLight Therapeutics is heading to the Nasdaq this morning via a $250 million IPO the biotech will use to advance its ...
(Reuters) -MapLight Therapeutics debuted on the Nasdaq on Monday with a valuation of $787 million, becoming the first company ...
MapLight Therapeutics, Inc. ( ($MPLT) ) has issued an announcement. MapLight Therapeutics, Inc. successfully closed its initial public offering ...
MapLight Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system ...
USA-based CNS specialist MapLight Therapeutics successfully made its public debut on Sunday evening, raising more than $250 ...
MapLight Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating ...
Neuropsychiatric disorder specialist MapLight Therapeutics has made its debut on the Nasdaq, raising $251 million and arriving on the scene valued somewhere north of $800 million.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback